Middle dose KL001

Phase 1Small molecule

ZZhejiang University

Middle dose KL001 is one of 19 small molecule programs targeting Hemophilia B. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia BActive, not recruiting

Hemophilia BPhase 1

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Hemophilia B

#DrugCompanyPhaseTrials

Recombinant Factor IX Coagulation

Pfizer

Approved

2 2

IB1001

MMedexus Pharma, Inc.

Phase 3

3 3

Translarna

BENEFIX

6 5

Recombinant Factor IX

BBaxalta now part of Shire

Phase 3

1 6

Rfix

Pfizer

Phase 3

3 7

Factor Ix

CSL Behring

Phase 3

3 8

Nonacog Alfa

Pfizer

Phase 3

3 9

Rix-FP

CSL Behring

Phase 3

3 10

Rfixfc

BBioverativ Therapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemophilia B2 trials

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Unknown status·ZZhejiang University·Phase 1·NCT06119659·9 enrolled

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Unknown status·—·Phase 1·NCT06125756·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Middle dose KL001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Middle dose KL001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Middle dose KL001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZhejiang University

Middle dose KL001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemophilia B2 trials

References

Drug Info

Quick Facts

Related News